The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Open accessAbstract
Purpose: Sacituzumab govitecan (IMMU-132) is an antibody–drug conjugate (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery of SN-38, the active metabolite of irinotecan. This phase I trial evaluated this ADC as a potential therapeutic for pretreated patients with a variety of metastatic solid cancers. Experimental Design: Sacituzumab govitecan was administered on days 1 and 8 of 21-day cycles, with cycles repeated until dose-limiting toxicity or progression. Dose escalation followed a standard 3 + 3 scheme with 4 planned dose levels and dose delay or reduction allowed. Results: Twenty-five patients (52–60 years old, 3 median prior chemotherapy regimens) were treated at dose levels of 8 (n = 7), 10 (n = 6), 12 (n = 9), and 18 (n = 3) mg/kg. Neutropenia was dose limiting, with 12 mg/kg the maximum tolerated dose for cycle 1, but too toxic with repeated cycles. Lower doses were acceptable for extended treatment with no treatment-related grade 4 toxicities and grade 3 toxicities limited to fatigue (n = 3), neutropenia (n = 2), diarrhea (n = 1), and leukopenia (n = 1). Using CT-based RECIST 1.1, two patients achieved partial responses (triple-negative breast cancer, colon cancer) and 16 others had stable disease as best response. Twelve patients maintained disease control with continued treatment for 16 to 36 weeks; 6 survived 15 to 20+ months. No preselection of patients based on tumor Trop-2 expression was done. Conclusions: Sacituzumab govitecan had acceptable toxicity and encouraging therapeutic activity in patients with difficult-to-treat cancers. The 8 and 10 mg/kg doses were selected for phase II studies. Clin Cancer Res; 21(17); 3870–8. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Upregulation of Trop-2 quantitatively stimulates human cancer growth
Trerotola, M., Cantanelli, P., Guerra, E., Tripaldi, R., Aloisi, A. L., Bonasera, V, Lattanzio, R., Lange, R. D., Weidle, U. H., Piantelli, M., et al. (2013) · Oncogene · doi:10.1038/onc.2012.36 · Cited by 331
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., & Goldenberg, D. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2939 · Cited by 311
Self-citationTrop-2 Is a Determinant of Breast Cancer Survival
Ambrogi, F., Fornili, M., Boracchi, P., Trerotola, M., Relli, V., Simeone, P., La Sorda, R., Lattanzio, R., Querzoli, P., Pedriali, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096993 · Cited by 221
Trop2: A possible therapeutic target for late stage epithelial carcinomas
Cubas, R., Li, M., Chen, C., & Yao, Q. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.001 · Cited by 192
Younes, A., Yasothan, U., & Kirkpatrick, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3629 · Cited by 170
Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy
Moon, S.-J., Govindan, S. V., Cardillo, T. M., D’Souza, C. A., Hansen, H. J., & Goldenberg, D. M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800719t · Cited by 159
Self-citationMilatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
Govindan, S. V., Cardillo, T. M., Sharkey, R. M., Tat, F. T., Gold, D. V., & Goldenberg, D. M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1170 · Cited by 136
Self-citationGovindan, S. V., Cardillo, T. M., Moon, S.-J., Hansen, H. J., & Goldenberg, D. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0586 · Cited by 111
Self-citation
Cited by
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
Self-citationAntibody–drug conjugates for cancer therapy
Thomas, A., Teicher, B. A., & Hassan, R. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30030-4 · Cited by 606
Tagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03489 · Cited by 543
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Metadata
- Authors
- Starodub, A. N., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., Wegener, W. A., Hamburger, S. A., Sharkey, R. M., & Goldenberg, D. M.
- Venue
- Clinical Cancer Research
- Published
- 2015-08-31
- Volume
- 21
- Issue
- 17
- Pages
- 3870-3878
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2107587681
- Cited by
- 340
- References
- 14
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-3321
- The paper
- Starodub, A. N., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., Wegener, W. A., Hamburger, S. A., Sharkey, R. M., & Goldenberg, D. M. (2015). First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-3321
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.